Print“By marrying Illumina’s expertise in sequencing with Partners Healthcare’s understanding of what’s needed for clinical utility, the two hope to leverage each other’s strengths to deliver a comprehensive sequencing and clinical reporting solution.”
Genetic sequencing tools company Illumina has entered into a strategic alliance with Partners Healthcare, the non-profit healthcare system founded by Brigham and Women's Hospital and Massachusetts General Hospital, to provide geneticist and pathologist networking tools and infrastructure to report and interpret data from genetic sequencing.
The companies did not disclose financial terms of the agreement, but said that they will integrate the functions of Illumina’s MiSeq sequencing system with Partners’ GeneInsight Suite, a platform that streatmlines the analysis, interpretation, and reporting of genetic test results. GeneInsight software has supported the interpretation and reporting for more than 24,000 complex genetic tests across multiple diagnostic reference laboratories since 2005, the companies said.
By marrying Illumina’s expertise in sequencing with Partners Healthcare’s understanding of what’s needed for clinical utility, the two hope to leverage each other’s strengths to deliver a comprehensive sequencing and clinical reporting solution for Illumina’s next-generation based content sets. The intent is to create a seamless process that begins with the MiSeq and delivers results directly into the GeneInsight tool so laboratory workers can interpret data. The new tools will link to Illumina's BaseSpace cloud computing platform and its MyGenome app for iPad, as well as to a clinical lab's local laboratory information system.
Matt Posard, senior vice president and general manager of Illumina's Translational and Consumer Genomics business said the alliance will “establish the new standard” in next generation sequencing clinical applications and enable “a truly integrated, high quality solution.”
Ilumina and Partners HealthCare will initially release the combined MiSeq-GeneInsight offering to a limited number of pilot customers that will include a select group of reference laboratories within leading academic institutions, molecular and genetic pathology laboratories looking to bring next-generation-based genetic testing in-house, as well as commercial reference laboratories.
Illumina plans to use the GeneInsight Lab application in its sequencing laboratory to support clinical interpretation and reporting. The company also said it remains on track to submit the MiSeq system to the U.S. Food and Drug Administration for 510(k) clearance before the end of the year.
September 13, 2012
http://www.burrillreport.com/article-illumina_and_partners_healthcare_ally_to_help_docs_interpret_genetic_data.html
.gif)
